Jazz Pharma officer plans $19.2M share sale

Jazz Pharmaceuticals plc (JAZZ) officer Robert Iannone has filed a notice to sell common shares under Rule 144.

Rhea-AI Filing Summary

Jazz Pharmaceuticals plc (JAZZ) officer Robert Iannone has filed a notice to sell common shares under Rule 144. The filing states an intention to sell 76,921 shares of JAZZ common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $19,207,099.95 and JAZZ common shares outstanding of 64,914,577 as of the planned sale date of August 27, 2026. The shares to be sold were acquired through an employee stock purchase plan, performance shares, stock option exercises, and restricted stock awards, including awards vesting between March 5, 2026 and June 30, 2026.

Key Figures

Shares to be sold: 76,921 shares of common stock Aggregate market value: $19,207,099.95 Shares outstanding: 64,914,577 shares +5 more

8 metrics

Shares to be sold 76,921 shares of common stock Planned Rule 144 sale through Morgan Stanley Smith Barney LLC

Aggregate market value $19,207,099.95 Aggregate market value of 76,921 JAZZ shares to be sold

Shares outstanding 64,914,577 shares JAZZ common shares outstanding referenced in the notice

Approximate sale date 08/27/2026 Planned date for execution of the Rule 144 sale

Employee Stock Purchase Plan shares 71 shares Common shares acquired under Employee Stock Purchase Plan dated 11/28/2025

Performance Shares 7,559 shares Common shares from performance shares dated 01/16/2026

Stock Option Exercise shares 55,788 shares Common shares from stock option exercise dated 08/27/2026

Restricted Stock 13,503 shares Common shares from restricted stock dated 03/05/2026

Key Terms

Rule 144, Employee Stock Purchase Plan, Performance Shares, Restricted Stock, +1 more

5 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Employee Stock Purchase Plan financial

"Common | 11/28/2025 | Employee Stock Purchase Plan | ISSUER"

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

Performance Shares financial

"Common | 01/16/2026 | Performance Shares | ISSUER"

Performance shares are a type of company stock given to executives or employees that only become theirs if the company meets specific goals, like hitting certain profits or growth targets. They motivate leaders to work toward the company’s success, because their additional shares depend on achieving these results.

Restricted Stock financial

"Common | 03/05/2026 | Restricted Stock | ISSUER"

Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.

Stock Option Exercise financial

"Common | 08/27/2026 | Stock Option Exercise | ISSUER"

A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for JAZZ insider Robert Iannone?

The filing discloses that officer Robert Iannone plans to sell 76,921 shares of Jazz Pharmaceuticals plc (JAZZ) common stock under Rule 144 through Morgan Stanley Smith Barney LLC, with an aggregate market value of $19,207,099.95 and an approximate sale date of August 27, 2026.

How many Jazz Pharmaceuticals (JAZZ) shares are planned to be sold under this Form 144?

The notice states that 76,921 shares of Jazz Pharmaceuticals (JAZZ) common stock are intended to be sold. This amount is reported in the broker section for Morgan Stanley Smith Barney LLC as the number of shares or units to be sold under Rule 144.

What is the reported market value of the JAZZ shares in this Form 144 filing?

The Form 144 reports an aggregate market value of $19,207,099.95 for the 76,921 shares of Jazz Pharmaceuticals (JAZZ) common stock that are intended to be sold through Morgan Stanley Smith Barney LLC.

How many Jazz Pharmaceuticals (JAZZ) shares are outstanding according to this filing?

The notice lists 64,914,577 shares of Jazz Pharmaceuticals (JAZZ) common stock as outstanding in connection with the planned Rule 144 sale. This figure is presented alongside the planned sale amount and aggregate market value as contextual share information.

How were the JAZZ shares to be sold by Robert Iannone acquired?

The shares were acquired through multiple equity programs: an Employee Stock Purchase Plan, performance shares, stock option exercises, and restricted stock. The remarks add that certain securities were acquired upon vesting of restricted stock between March 5, 2026 and June 30, 2026.

When is the approximate sale date for the JAZZ shares in this Form 144?

The approximate sale date indicated is August 27, 2026. This date appears in the section describing the planned sale of 76,921 shares of Jazz Pharmaceuticals (JAZZ) common stock to be executed through Morgan Stanley Smith Barney LLC on the NASDAQ market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/27/2026 - 04:32 PM EDT Accepted by SEC EDGAR 08/27/2026 - 04:31 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001737329
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY
SEC File Number	001-33500
Address of Issuer	Fifth Floor, Waterloo Exchange Waterloo Road Dublin 4 IRELAND D04 E5W7
Phone	011-353-1-634-7800
Name of Person for Whose Account the Securities are To Be Sold	ROBERT IANNONE
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	76921	19207099.95	64914577	08/27/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	11/28/2025	Employee Stock Purchase Plan	ISSUER			71	11/28/2025	Cash
Common	01/16/2026	Performance Shares	ISSUER			7559	01/16/2026	Not Applicable
Common	08/27/2026	Stock Option Exercise	ISSUER			55788	08/27/2026	Cash
Common	03/05/2026	Restricted Stock	ISSUER			13503	03/05/2026	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	The securities to be sold were acquired upon the vesting of restricted stock during the period of 3/05/2026 through 6/30/2026.
Date of Notice	08/27/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/28/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Robert Iannone
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)